US 10828297

I'll verify against live sources before summarizing.

US Patent 10,828,297 B2 — Verification Summary

Sourcing note (read first): Your prompt states the current date is April 26, 2026, but my system date is 2026-09-17, and search results I retrieved include Petitions/PTAB papers and news items dated June–August 2026. I am reporting what the sources actually say rather than assuming a date. Also note that several PTAB documents render the patent owner's name as "Helsinki" — that is an OCR/text-extraction artifact of Helsinn, not a different entity.

1. Bibliographic data (confirmed against the full patent text on Google Patents and secondary databases)

Source: https://patents.google.com/patent/US10828297/en

2. Abstract (verbatim)

"Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery."

3. Plain-language overview of the independent claims

The patent's three independent claims are all method-of-use claims directed to a patient receiving highly emetogenic cancer chemotherapy (HEC), and all three share the same core step: inducing therapeutically effective blood levels of palonosetron and netupitant in a combination regimen with dexamethasone.

• Claim 1 — Preventing acute and delayed nausea and vomiting. Administering the palonosetron + netupitant combination (with dexamethasone) so that the patient's blood levels of both actives are therapeutically effective, for the purpose of preventing nausea and vomiting in both the acute (0–24 h) and delayed (25–120 h) phases of HEC-induced emesis.
• Claim 2 — Achieving complete response. Same combination step, but the recited purpose is achieving "complete response" during the acute and delayed phases. (In the specification, complete response = no emetic episodes and no rescue medication.)
• Claim 3 — Preventing nausea. Same combination step, but the recited purpose is preventing nausea specifically (as distinct from vomiting) across the acute and delayed phases.

Dependent-claim themes (claims 4–23), which narrow the three independents in parallel groups:

• Route: blood levels induced by an intravenous anti-emetic regimen administered prior to the chemotherapy (claims 4, 13, 19).
• Bioequivalence: blood levels equivalent to those from 50–500 mg netupitant free base + 0.075–1.0 mg palonosetron HCl administered orally (claims 5, 14, 20), and more narrowly equivalent to 300 mg netupitant free base + 0.56 mg palonosetron HCl orally (claims 6, 15, 21). Note the 0.56 mg figure corresponds to 0.5 mg palonosetron free base per Table 1.
• Receptor-occupancy limitation: netupitant occupies ≥70% of the patient's striatum NK1 receptors 72 hours after administration (claims 7, 16, 22).
• Outcome-specific claims: complete response (8); no emesis (9); no rescue medication (10); prevents nausea (11, 17).
• Independence-of-effect claims: the netupitant blood levels alone are effective to prevent acute and delayed nausea/vomiting (12), to produce complete response (18), and to prevent nausea (23).

Important structural note: every independent claim affirmatively recites "in a combination regimen with dexamethasone." The claims are drafted around induced blood levels rather than around administration of a specific fixed-dose oral capsule — which is why the specification's oral-capsule/soft-gel subject matter (claims 34–51 described in the family's related filings, e.g. the Table 1/Table 2 formulations) appears predominantly in the specification and in sibling patents rather than in the '297 claims.

4. Litigation and PTAB activity (as reflected in the sources retrieved)

• District court: D.N.J. dockets 2:22-cv-04635 and 3:22-cv-04635, filed 2022-07-18, captioned Helsinn Healthcare SA v. Gland Pharma Ltd, asserting 10,828,297 together with 9,908,907, 9,403,772, 10,624,911, 8,426,450, 8,895,586, 11,312,698, 10,208,073, 10,717,721 and 9,186,357. One docket shows termination dated 2022-12-23. Sources: ipwatchdog.com (July 2022 roundup) and drugpatentwatch litigation tables.
• PTAB: IPR2025-00949, Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A., filed 2025-05-01, challenging U.S. 10,828,297 B2; institution decision 2025-11-19; status "Trial Instituted." It was filed alongside IPR2025-00945 ('826), -00946 and -00947 ('357), and -00948 ('515). The Acting Director declined to exercise discretionary denial, referring the petitions to the Board (Decision in the five consolidated-style cases; Director's memo citing, inter alia, that the examiner allowed the claims based on "evidence of synergy (unexpected result) from the combination of netupitant and palonosetron").
• CAFC 2026 dockets: ⚠️ I found no Federal Circuit appeal docket or decision specifically involving U.S. 10,828,297. My searches for "10828297" plus CAFC/2026 returned only unrelated 2026 Federal Circuit matters (Spero v. Mercedes-Benz, AGI/Farmers Edge, Ollnova/ecobee, Ironburg/Valve, Teva v. Lilly, USAA, range-of-motion, Keysight/Centripetal, etc.). Given the IPR was instituted 2025-11-19, a final written decision would ordinarily be expected on roughly a 12-month clock, with any appeal to the Federal Circuit only after that — so it is plausible (but not confirmed by any source I found) that no CAFC appeal yet exists for this patent. Treat this as an uncertainty rather than a negative finding.

5. Related family members (for context; not claims of this patent)

US 8,951,969; US 9,186,357; US 9,943,515; US 8,623,826; US 11,559,523; US 12,042,494 — all sharing the 2009-11-18 priority per Google Patents' "Priority Applications" table.

6. Explicit uncertainties

1. No authoritative CAFC 2026 docket for '297 was located — absence of evidence here is not proof of absence.
2. The issue date, filing date, priority date, inventors, assignee, abstract and claim text above are taken directly from the full patent document supplied in my working context and from the Google Patents page, so those are high-confidence.
3. Secondary databases disagree in minor ways on expiry labels: pharmakb lists both 2030-11-18 and 2030-12-17 against the netupitant/palonosetron family, while the Google Patents record for '297 specifically gives 2030-12-17 as the adjusted expiration (consistent with PTA). I have not independently recomputed PTA.
4. The IPR's substantive merits (whether the "unexpected synergy" holding survives) are contested; the PTAB documents I retrieved are petitioner briefing and the Director's referral decision, not a final written decision on '297.

I'll search for litigation involving US patent 10828297.

Let me gather more details on the specific cases found.

Let me verify completeness with additional targeted searches.

Litigation Involving U.S. Patent No. 10,828,297

I searched patent-litigation aggregators (Unified Patents litigation/PTAB portal, Docket Alarm, DrugPatentWatch, CourtListener, IPWatchdog) for the specific number 10,828,297. Note at the outset: I did not auto-correct any identifiers — everything below is reproduced literally from the sources, and where sources disagree (e.g., the division prefix on the district-court case number) I flag it rather than resolve it.

I identified one district-court case and one PTAB proceeding naming the '297 patent.

1. District Court Litigation

Case: Helsinn Healthcare S.A. v. Gland Pharma Limited

• Plaintiff: Helsinn Healthcare S.A. (Switzerland; current assignee of the '297 patent per the patent record)
• Defendant: Gland Pharma Limited (India)
• Jurisdiction/Court: U.S. District Court for the District of New Jersey
• Case Number: 3:22-cv-04635 (ZNQ)(LHG) — the complaint header and CourtListener docket read "3:22-cv-04635-ZNQ-JBD / 3:22-cv-04635." Gland's counterclaims and some aggregators reference the same action as 2:22-cv-04635. The Google Patents "litigation" panel lists both 2:22-cv-04635 and 3:22-cv-04635. This appears to be the same Newark/Trenton division-prefix discrepancy rather than two separate suits, but I cannot confirm that from the sources.
• Cause of Action: 35:271 Patent Infringement (Hatch-Waxman / Paragraph IV)
• Filing Date: July 18, 2022
• Assigned Judge: Zahid N. Quraishi; referred to Magistrate Judge J. Brendan Day (LHG per the judgment caption)
• Patent asserted: U.S. 10,828,297 was one of ten Helsinn patents asserted, together with U.S. 8,426,450; 8,895,586; 9,186,357; 9,403,772; 9,908,907; 10,208,073; 10,624,911; 10,717,721; and 11,312,698.
• Basis: Gland's ANDA No. 217374 (generic EQ 11.75 mg/mL fosnetupitant chloride hydrochloride and 0.0125 mg/mL palonosetron hydrochloride, 235 mg/0.25 mg per 20 mL single-dose vials for IV administration) with Paragraph IV certifications against the asserted patents.
• Outcome/Status: Resolved by Consent Judgment and Dismissal Order — signed by Judge Quraishi January 18, 2023 (entered January 19, 2023; Document #50). All claims, counterclaims, and affirmative defenses were dismissed. Under the consent judgment, Gland admitted that submission of ANDA No. 217374 was a technical act of infringement under 35 U.S.C. § 271(e)(2)(A), and was enjoined from marketing the ANDA product until a specified (redacted) date. Gland's invalidity/non-infringement counterclaims were not adjudicated. DrugPatentWatch lists a Date Terminated of 2022-12-23, which is inconsistent with the January 2023 judgment date — I flag this discrepancy rather than reconcile it.
  • Sources: DrugPatentWatch case page; CourtListener — Complaint #1; CourtListener — Order #50; Consent Judgment PDF; IPWatchdog roundup

2. PTAB Proceeding (Inter Partes Review)

Proceeding: Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A., IPR2025-00949

• Petitioner: Azurity Pharmaceuticals, Inc.
• Patent Owner (Respondent): Helsinn Healthcare S.A.
• Patent challenged: U.S. 10,828,297 B2 (Respondent Application No. 15923050; Tech Center 1600)
• Filing Date: May 1, 2025
• Institution Decision Date: November 19, 2025
• Status: Trial Instituted (pending) — as of the most recent data retrieved.
• Panel: Administrative Patent Judges Michael J. Fitzpatrick, Sheridan K. Snedden, and Christopher J. Paulraj
• Counsel: Petitioner — Richard Torczon et al.; Patent Owner — Eric Dittmann et al.
• Context: This is one of a family of five related Azurity IPR petitions against Helsinn patents — IPR2025-00945 ('826 patent), IPR2025-00946 and -00947 ('357 patent), IPR2025-00948 ('515 patent), and IPR2025-00949 ('297 patent). In IPR2025-00948 the Board noted that the Acting Director denied Helsinn's discretionary-denial request on September 19, 2025 and referred the petition to the Board. Azurity's challenge to the '297 claims focuses on alleged obviousness over prior art (e.g., Herrstedt, Bös, Herrington) and on Helsinn's asserted "unexpected synergy" and alleged misrepresentations/omissions of data during prosecution.
  • Sources: IPVerse IPR2025-00949 case details; Docket Alarm IPR2025-00949; IPR2025-00948 Institution Decision (listing the five related IPRs); Unified Patents PTAB entry for IPR2025-00949

Summary Table

Caveats

• Completeness: I found these two matters only. It is possible that additional proceedings (e.g., foreign actions, additional ANDA suits, appeals, or a CAFC appeal from the IPR) exist that were not surfaced in the searches. I found no CAFC appellate docket specifically naming 10,828,297, and no other district-court action naming it beyond the Gland case.
• Overlapping-family cases: Several older Helsinn cases (e.g., Helsinn v. Hospira, D.N.J. 3:15-cv-02077; Helsinn v. Dr. Reddy's, D.N.J. 2:14-cv-04274) involve the same ALOXI®/Akynzeo® family but assert different patent numbers (e.g., 7,947,724; 7,947,725; 7,960,424; 8,598,219; 8,729,094). Those are not actions on 10,828,297 and I have excluded them, per the instruction not to report similar numbers.
• Verification: Litigation-status data from third-party aggregators may lag or contain errors (e.g., the conflicting termination date noted above). For docket-authoritative confirmation, PACER/Unified Patents should be checked directly.

I'll start by pulling the structured record and then searching for any proceedings, including the IPR2025-00949 noted in the patent page metadata.

Key hit: IPR2025-00949 (Azurity v. Helsinn). Let me pull the institution decision, panel, and any subsequent developments.

Let me get the institution decision for -00949 itself, the scheduling order dates, and check for later 2026 events.

PTAB Proceedings — US 10,828,297 ("Compositions and methods for treating centrally mediated nausea and vomiting")

⚠️ Data discrepancy flagged up front

The structured "PTAB proceedings on file" block states that the USPTO ODP API returns no AIA trial proceedings for this patent. That is wrong (or stale). Both the Google Patents record for US10828297B2 and independent PTAB dockets confirm one live AIA trial: IPR2025-00949. A second metadata defect on the Google Patents page: it tags the IPR2025-00949 entry to the "Unified Patents PTAB Data" feed with the petitioner field blank. There is no evidence Unified Patents filed anything here — the real petitioner is Azurity Pharmaceuticals, Inc. Per the operating rules, I prefer the search results over both the flat "no proceedings" block and the vendor label.

Proceedings overview

One (1) AIA trial on file for the '297 patent: IPR2025-00949, Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A. — status "Trial Instituted" (institution granted 2025-11-19); claims invalidated: none; claims sustained: none; settled: none; institution denied: none (the patent owner's discretionary-denial request was denied by the Acting Director on 2025-09-19). No Final Written Decision has issued. Bottom-line defensive posture for a defendant today: this is not a "hardened, survived-two-IPRs" patent and it is not a "claims-1-5-are-canceled" patent — it is a patent with all 23 claims under § 103 attack in a live trial whose FWD is statutorily due on or about 2026-11-19. A defendant gets no free ride from a prior adjudication; its value is in the record Azurity is building (and the discovery Azurity's expert is being cross-examined on), which is usable as persuasive, not binding, authority.

IPR2025-00949 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.

• Type: Inter Partes Review (35 U.S.C. §§ 311–319)
• Filed: 2025-05-01
• Status: Trial Instituted — institution decision dated 2025-11-19; scheduling order issued the same day. Tech Center 1600, Art Unit 1612.
• Judge panel: APJs Michael J. Fitzpatrick, Sheridan K. Snedden, and Christopher G. Paulraj (the Board's orders render the third surname "PAULRAIJ"; the case docket also lists "CHRISTOPHER J. PAULRAJ" — a docketing artifact, not a fourth judge). APJ Snedden authored the pro hac vice order.
• Counsel: Petitioner — Richard Torczon, Jad Mills, Michael Rosato, Wendy Devine (Wilson Sonsini Goodrich & Rosati). Patent Owner — Eric Dittmann (lead) et al., with Melanie R. Rupert and Justin T. Fleischacker admitted pro hac vice as back-up counsel on 2026-01-13 (motions filed 2026-01-06, unopposed).
• Petition grounds: challenge to claims 1–23 — that is every claim of the patent — on § 103 obviousness (pre-AIA §§ 102/103 per the family's petitions). Helsinn's own discretionary-denial brief characterizes Azurity's base references as "Herrstedt" (EX1010) and "Bös" (EX1014), which "are cited by Azurity for the bulk of the claim limitations." Helsinn stresses that Bös is already printed on the face of the '297 patent and that Herrstedt is "the same" as the prosecution prior art ("Reddy", EX1021). Azurity's expert is Stephen J. Peroutka, M.D., Ph.D. (Caveat: I did not retrieve the '297 petition's own ground-by-ground table, so I cannot state the exact reference combination driving each dependent claim the way I can for the sibling '357 petition.)
• Institution decision: Instituted 2025-11-19. Two-stage history worth knowing:
  1. 2025-09-19 — Acting Director Coke Morgan Stewart, "Decision Referring the Petitions to the Board." Helsinn sought discretionary denial under the Acting Director's 2025-03-26 Memorandum on Interim Processes for PTAB Workload Management (advanced by Helsinn's two-part pitch: strong "settled expectations" from an old patent family subject to a terminal disclaimer over the '826 patent, and no art more pertinent than what the examiner already saw). The Acting Director denied discretionary denial across the consolidated family set (IPR2025-00945, -00946, -00947, -00948, -00949), reasoning that although age/commercialization/prior assertions favor denial, "[o]ther considerations … counsel against" it — no parallel Fintiv proceeding existed, and, critically, "Petitioner … persuasively argues that the data and evidence presented to the patent examiner indicates that the results may not have been unexpected, but rather may have been consistent with prior art disclosures of the claimed compounds and their use." The Director specifically pointed to data showing "the overall effect for no nausea and no significant nausea for palonosetron and netupitant was nearly the same as that of palonosetron and aprepitant" — i.e., the Office's material-error/§ 325(d) hook. The petitions were referred to the Board "to handle the cases in the normal course." This is a significant adverse ruling for Helsinn: it defuses the § 325(d) and "settled expectations" arguments a defendant would otherwise have to overcome.
  2. 2025-11-19 — Board institution decision (paper not yet in my retrieved set, but the Board's own scheduling order issued that date confirms institution).
• Final Written Decision: None as of today (2026-09-17). No claim of the '297 patent has been canceled, and none has been confirmed patentable by the Board. Statutory deadline under § 316(a)(11) is ~2026-11-19 (extendable up to six months for good cause). Any statement that claims 1–23 (or any subset) are dead would be fabrication at this stage.
• Key trial milestones on the record:
  • 2025-11-19 — Scheduling order (Due Dates 1–8; PO response/MTA at Due Date 1).
  • 2025-12-26 — Helsinn noticed the cross-examination of Dr. Peroutka for 2026-01-13, expressly agreed as a single combined deposition in IPR2025-00945/00946/00947/00948/00949, transcript admissible in all five — so any Peroutka admissions touch this patent too.
  • 2026-01-13 — Pro hac vice grant; Peroutka deposition taken (Palo Alto, CA).
  • 2026-02-25 — Patent Owner exhibit filed including deposition testimony spanning the five IPRs ("the IPRs we're going to be discussing today are IPR2025-00945, 946, 947, and 948 and 949").
• Settlement / termination: None. No termination-on-settlement certificate appears; the proceeding is proceeding on the merits.
• Appeal: None possible yet (no FWD). No CAFC docket exists for an appeal of this IPR.
• Defensive value: The most useful thing Azurity has produced for any defendant is not a judgment — it is a fully developed prosecution-error narrative: the Rule 132 "unexpected synergy" declaration by Rossi and Pietra, which the examiner credited in allowing the '297 claims ("evidence of synergy (unexpected result) from the combination of netupitant and palonosetron"), is attacked as cherry-picked — internal Helsinn study data (NETU-07-07, NETU-08-18) allegedly altered/suppressed, Emend-label "complete protection" data omitted, and Grunberg (2009) rendered non-comparable on dosing. If the Board credits any of this on 2026-11-19, the terminal-disclaimer-linked family claims fall together. Until then, treat the '297 patent as live and presumed valid, and do not rely on the IPR as an estoppel shield.

Related family activity (context only — not proceedings on the '297 patent)

• Azurity's five-petition campaign (all filed 2025-05-01): IPR2025-00945 (US 8,623,826), IPR2025-00946 and IPR2025-00947 (both US 9,186,357), IPR2025-00948 (US 9,943,515), and IPR2025-00949 (US 10,828,297 — this patent). All five were carried in the same 2025-09-19 Director referral and the same 2025-11-19 institution/scheduling wave. If a defendant is accused under the whole Akynzeo® Orange-Book family, the IPRs live or die together.
• Dr. Reddy's earlier run at Helsinn (2015–2016): IPR2015-01550, -01551, -01553 and PGR2016-00007, -00008 — all institution denied. These are not on the '297 patent (which was filed 2018 and issued 2020) and cannot be cited as the '297 patent "surviving IPRs." They are listed here only to show Helsinn's historical success rate in fending off institution on its earlier palonosetron patents.

Strategic summary

Claim status. There is no claim-level adjudication of the '297 patent. Claims 1–23 are all CHALLENGED, none CANCELED, none SUSTAINED. Independent claims 1, 2, and 3 each recite inducing "therapeutically effective blood levels of palonosetron and netupitant in a combination regimen with dexamethasone" for HEC patients to (1) prevent acute and delayed nausea/vomiting, (2) achieve complete response across acute and delayed phases, and (3) prevent nausea across acute and delayed phases. Dependent claims 4–23 add IV administration, dose-equivalents (50–500 mg netupitant free base; 0.075–1.0 mg palonosetron HCl; 300 mg / 0.56 mg), and the ≥70% striatum-NK1-occupancy-at-72-hours limitation (claims 7, 16, 22). Note the patent's adjusted expiration is 2030-12-17, and it is subject to a terminal disclaimer over US 8,623,826, so nullification of the '826 claims would be a cross-cutting event — which is why the Office treated the five petitions as one family set.

Estoppel landscape. No § 315(e)(2) estoppel exists against anyone yet, because estoppel attaches only after a Final Written Decision. Azurity will be estopped, upon FWD, from asserting in litigation any ground it raised or reasonably could have raised in the '297 IPR; that estoppel runs to Azurity and its privies only and gives a different defendant nothing — third parties are not estopped by another party's IPR. What a current defendant inherits instead is the § 315(b) one-year clock (running from service of a complaint alleging infringement) and the practical reality that the highest-value art — Herrstedt, Bös, Herrington, Hargreaves, ALOXI label, Emend label, Bonadeo, and the Grunberg data — is already in the public PTAB record and already before the examiner, which raises § 325(d) discretion risk for any duplicative re-filing. The path most likely to succeed for a new defendant is different art plus the § 112 attack the district-court counterclaims already plead (indefiniteness/enablement of "acute and delayed") — a ground the Board cannot reach in an IPR.

Pattern signals. (i) Same petitioner, five patents, filed same day — Azurity is running a coordinated, funded generics/portfolio-clearing campaign, not a one-off defensive filing; Wilson Sonsini is petitioner counsel, and Helsinn is paying for a heavyweight defense team (Dittmann lead + two pro hac vice litigators admitted 2026-01-13). (ii) The patent owner is fighting hard on procedure — Helsinn went straight to the Acting Director for discretionary denial under the March 2025 workload-management memo and lost, a notable 2025-era development. (iii) No defensive aggregator (Unified Patents or similar) is in the chain on this patent; the Google Patents "Unified Patents" label is a data-vendor artifact, not a filer. (iv) In district court, Helsinn asserted the '297 patent against Gland Pharma — Helsinn Healthcare S.A. v. Gland Pharma Ltd., D.N.J. 2:22-cv-04635 (filed 2022-07-18; terminated 2022-12-23, consistent with a settlement/dismissal roughly five months in). Gland counterclaimed for a declaration of invalidity of the '297 patent asserting § 103 over the ALOXI Label, Bös, Dewan, and the EMEND Label, plus § 112 indefiniteness/non-enablement as to "acute and delayed." Azurity's later answer brief characterizes that Gland outcome as one Helsinn may simply have "paid Gland to go away" — an unresolved point the Board may or may not care about.

Recommended next steps

1. Correct the file. The ODP-derived "no PTAB activity" representation is inaccurate. Pull the actual papers from PTAB E2E / PTACTS: the 2025-11-19 institution decision and scheduling order (IPR2025-00949), the 2025-09-19 Acting Director referral decision (https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1557835](/patent/1557835)/download-documents?artifactId=y6IrpDZshKUiiFxv9niHSqbJgCBiIoOXIntwhciUvoy8nIRpQCyqXDI), and Helsinn's discretionary-denial request (same petition record, https://ptacts.uspto.gov/ptacts/public-informations/petitions/1557835/download-documents). Docket mirror with the filing timeline: https://gaeflexstaging-dot-docketupdate.appspot.com/cases/PTAB/IPR2025-00949/AZURITY_PHARMACEUTICALS_INC._v._Helsinn_Healthcare_S.A/; case summary: https://ipverse.greyb.com/ptab-web/cases/case-details/IPR2025-00949.
2. Diary the FWD. Trial deadline is on or about 2026-11-19 (one year from institution under § 316(a)(11); extendable up to six months). Watch for (a) Helsinn's contingent motion to amend (Due Date 1 — a successful MTA would substitute claims and moot part of the exposure, and would also create new claim language to re-analyze), (b) any request for Director Review of the institution decision, and (c) whether the Board reaches all 23 claims or issues a partial FWD.
3. If you are a defendant being asserted under US 10,828,297: do not cite any canceled claim (none exist) and do not describe the patent as having "survived IPRs." Instead, incorporate Azurity's record — the Director's finding that the examiner's Rule 132 "unexpected synergy" evidence "may not have been unexpected," plus the alleged suppression/alteration of the NETU study data — into your inequitable-conduct/unenforceability and obviousness narratives. Then (i) calendar your § 315(b) date if you have been served, (ii) consider whether you are in privity with Azurity (you are not, absent a funding/control relationship), and (iii) develop prior art and § 112 theories that Azurity did not raise, since § 325(d) and issue-preclusion-by-record will otherwise blunt a duplicative IPR.
4. Do not rely on the Gland case. Helsinn v. Gland Pharma, D.N.J. 2:22-cv-04635 was terminated 2022-12-23 without any reported validity judgment; Gland's counterclaims (CourtListener, https://storage.courtlistener.com/recap/gov.uscourts.njd.[499051](/patent/499051)/gov.uscourts.njd.499051.25.0.pdf) are allegations, not holdings. There is no prior FWD and no Federal Circuit decision on any claim of the '297 patent to cite.

Confidence notes: the existence, petitioner, filing date, instituted status, institution date, panel, and counsel for IPR2025-00949 are well-corroborated across the Google Patents record, PTAB docket mirrors, and PTAB documents. The '297 petition's precise ground-by-ground reference mapping and the text of the 2025-11-19 institution decision itself are the two items I could not fully verify; the claim scopes and the Herrstedt/Bös base references are drawn from Helsinn's own PTAB briefing on the '297 petition. Treat those two items as unconfirmed.

I'll research the assignment record for US 10828297 before writing up the sections.

Let me dig into the recorded assignments and the litigation/PTAB context.

I still need reel/frame data. Let me query the USPTO assignment records directly.

Ownership Analysis — US 10,828,297 B2

Scope note / data caveat: This patent's post-issuance records are visible in the reassignment feed on Google Patents (which mirrors USPTO assignment data), but that feed does not expose reel/frame numbers, and I was not able to retrieve the Assignment Center detail pages (reel/frame + correspondent of record) for US 10,828,297 within this session. I therefore report the assignment events with confidence and explicitly mark the reel/frame and correspondent fields as not retrieved rather than inventing them. Verify at USPTO Assignment Center (search patent number 10828297).

Inventors

Named inventors on the face of the patent (US 10,828,297 B2):

Patterns worth noting:

• No inventor-departure / fire-sale precursor. These are long-tenured Helsinn personnel (Cantoreggi and Bonadeo appear repeatedly across Helsinn's palonosetron and netupitant families, including the earlier CINV patents at issue in Helsinn v. Teva). There is no evidence of a coordinated inventor exodus within 12 months of filing.
• Records discrepancy to flag: the 2018-03-23 assignment record also lists Riccardo Braglia as an assignor, but Braglia is not a named inventor on the '297 patent. Braglia is Helsinn Group's CEO (per Helsinn's own Feb 2, 2015 press release) and was a declarant in the related palonosetron CINV prosecution. The most likely explanation is that the recorded assignment instrument covered the family/related applications rather than the '297 inventors alone. This is a title-record bookkeeping artifact, not an ownership transfer.
• The '297 is a continuation (app. 15/923,050, filed 2018-03-16) claiming priority from PCT/IB2010/003106 (2009-11-18 priority). The original 2010 application named a partly different inventive entity, which is why the 2018 instrument sweeps in additional names.

Original assignee

Helsinn Healthcare SA (Via Pian Scairolo 9, Lugano/Pazzallo 6912, Switzerland) — assignee on the issued patent, and still the assignee today.

• Primary line of business: privately held, family-owned Swiss specialty pharmaceutical group (founded 1976) focused on cancer supportive care. Helsinn's stated model is in-licensing molecules, developing and registering them, then out-licensing to a global partner network — i.e., it is an operating drug developer with its own GMP manufacturing in Switzerland and Ireland, plus a direct US commercial arm, Helsinn Therapeutics (U.S.), Inc. (commercial organization established March 2013).
• Product embodying the claims — yes. The '297 is Orange Book–listed for AKYNZEO, NDA 205718-001 (netupitant 300 mg / palonosetron HCl 0.5 mg oral capsule, approved Oct 10, 2014) with use code U-2293, and for AKYNZEO IV, NDA 210493 (fosnetupitant chloride hydrochloride / palonosetron HCl, approved 2018/2020) with use code U-2301. Listed expiry 2030-12-17.
• Current status: operating, not dissolved or in bankruptcy. A blanket security interest was granted to Hamilton SA LLC across three Helsinn entities on 2022-12-30 and released on 2023-09-20 — consistent with a secured financing that was repaid or refinanced, not with insolvency.

Assignment timeline

Three recorded assignment events are visible. Reel/frame and correspondent of record were not retrievable in this session — do not treat the blank fields below as "none."

1. Executed 2018-03-16 (filing date) / recorded 2018-03-23 — Reel NNNNNN/NNNN (not retrieved)

• Conveyance: Assignment of assignors' interest
• Assignor: Daniele Bonadeo; Riccardo Braglia; Roberta Cannella; Sergio Cantoreggi; Giorgia Rossi; Fabio Trento
• Assignee: Helsinn Healthcare SA
• Correspondent: not retrieved
• Context: Title normalization — routine inventors-to-company assignment recorded seven days after Helsinn filed continuation 15/923,050; no third party involved.

2. Executed/recorded on or about 2022-12-30 — Reel NNNNNN/NNNN (not retrieved)

• Conveyance: Security Interest (Security Agreement)
• Assignor: Helsinn Healthcare SA; Helsinn Birex Pharmaceuticals Limited; Helsinn Therapeutics (U.S.), Inc.
• Assignee: Hamilton SA LLC
• Correspondent: not retrieved
• Context: Securitization — a single secured-party/collateral agent took a lien over the patent portfolios of all three Helsinn operating entities. Title did not move; this is not a transfer to an asserter.

3. Executed/recorded on or about 2023-09-20 — Reel NNNNNN/NNNN (not retrieved)

• Conveyance: Release by Secured Party (Release)
• Assignor: Hamilton SA LLC
• Assignee: Helsinn Healthcare SA; Helsinn Birex Pharmaceuticals Limited; Helsinn Therapeutics (U.S.), Inc.
• Correspondent: not retrieved
• Context: Release of the 2022 security interest; collateral lien terminated and Helsinn entities restored to unencumbered record title.

Non-assignment family events (for context, not part of the assignment chain): continuation US 17/075,757 → US 11,559,523 (priority link 2020-10-21) and US 18/082,737 → US 12,042,494 (2022-12-16), both bearing the same title and the same 2009-11-18 priority. Helsinn is keeping the family alive — classic brand life-cycle management, not asset monetization.

Litigation / challenge overlay: Helsinn Healthcare SA v. Gland Pharma Ltd., D.N.J. 2:22-cv-04635 (and 3:22-cv-04635), filed July 2022, asserting the '297 among ten Orange Book patents after Gland's Paragraph IV notice on its fosnetupitant/palonosetron ANDA (No. 217374). PTAB IPR2025-00949 (Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.), filed 2025-05-01, instituted 2025-11-19, patent owner app. 15/923,050.

Timeline diagram

timeline
    title Ownership of US 10828297
    2009 : Earliest priority date
    2010 : PCT application filed
    2018 : Continuation filed by Helsinn
         : Inventors assign rights to Helsinn
    2020 : Patent issued to Helsinn Healthcare SA
    2022 : Gland ANDA suit filed
         : Security interest to Hamilton SA LLC
    2023 : Security interest released
    2025 : Azurity IPR instituted

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The only non-Helsinn assignee ever recorded is Hamilton SA LLC, and its conveyance is expressly a Security Interest (2022-12-30) later released (2023-09-20). A collateral agent under a security agreement takes no title and asserts nothing. No "IP / Holdings / Ventures / Licensing" entity appears anywhere in the chain, and no product-free assignee holds record title.

2. Known asserter in the chain — not present. Current assignee is Helsinn Healthcare SA; prior assignors are Helsinn operating entities (Helsinn Birex Pharmaceuticals Limited, Helsinn Therapeutics (U.S.), Inc.) and the inventors. No match against Acacia, Marathon, IV, IPNav, Wi-LAN, Conversant/Mosaid, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, DGC, or Spangenberg entities. Unified Patents' page for this patent lists Parent Company: Helsinn Healthcare SA.

3. Repeat correspondent across the chain — unclear. Correspondent-of-record names were not retrievable this session, so recurrence cannot be tested. This is the one signal a full Assignment Center pull could flip, and it is worth pulling the reel/frame detail pages for all three records. Given the assignees here are a single corporate family plus one collateral agent, a repeat correspondent would most likely be Helsinn's own outside patent counsel or the lender's counsel — neither of which is an NPE tell.

4. Cascading transfers — not present. Three records over ~5.5 years, two of which are a matched security-interest/release pair. No chained LLCs, no sub-24-month relay.

5. Pre-litigation transfer — not present. The Gland suit was filed July 2022; the nearest assignment is the 2022-12-30 security interest, which post-dates the complaint. There is no assignment in the six months preceding the first suit (only the routine 2018-03-23 inventor assignment, ~4 years earlier). Title has been continuously held by Helsinn since 2018 — no standing/venue engineering.

6. Bankruptcy fire-sale — not present. No Chapter 7/11 for any Helsinn entity appears; the 2023 release is inconsistent with insolvency (secured party released rather than foreclosed). Helsinn is a private Swiss family group, not a public-company patent seller.

7. Privateering — not present. Helsinn asserts directly, in its own name, against actual ANDA competitors (Gland Pharma, and the broader Akynzeo Paragraph IV cohort). There is no transfer to an NPE to assert on Helsinn's behalf, and no SEC 8-K/10-K transfer event (Helsinn is not SEC-reporting).

8. Defensive aggregator — not present. Chain does not terminate at RPX, AST, LOT, Unified Patents, or OIN. Note the direction of travel is the opposite: Unified Patents and Azurity are the challengers and defendants here, and Azurity's instituted IPR2025-00949 is an attack on this patent, not a defensive acquisition of it.

Verdict

Operating-company assertion.

Helsinn Healthcare SA — the original and current assignee — is an operating pharmaceutical developer that ships AKYNZEO (NDA 205718 / NDA 210493), the product embodying the '297 claims, and it litigates this patent in its own name against generic ANDA filers (Gland Pharma, D.N.J. 2:22-cv-04635, filed July 2022). The only non-Helsinn entity ever on the record is Hamilton SA LLC under a security interest dated 2022-12-30 and released 2023-09-20 — a financing lien, not an NPE transfer. Zero of the eight NPE signals are present on the available evidence; only the repeat-correspondent check is unanswered.

Verify: USPTO Assignment Center — search 10828297 — pull the three records to fill in reel/frame and correspondent of record.

I'll research this patent number and its cited prior art. Let me start with several searches.

Let me dig into the specific citations and the IPR proceedings for this patent.

Let me get the specific patent citation list and the IPR2025-00949 grounds for this patent.

Prior-Art Analysis — US 10,828,297 B2

A note on method and confidence. I searched for the references cited in and against US 10,828,297. My tool access was cut off before I could load the complete "Patent Citations / References Cited" table from the Google Patents page for this patent. What follows is therefore reconstructed from (a) the patent's own specification (authoritative text supplied), (b) the prosecution record of application 15/923,050 as quoted in the PTAB filings for this patent, (c) the exhibit lists in the pending IPRs (IPR2025‑00945/‑947/‑949), and (d) PubChem's patent page. Where I could not confirm an exact date or full title from a primary source, I say so rather than guess.

1. The patent being analyzed (verified)

Claim structure (what prior art must meet):

• Claims 1–3 (independent): methods of (1) preventing acute and delayed CINV, (2) achieving complete response, and (3) preventing nausea — all by inducing therapeutically effective blood levels of palonosetron and netupitant in a combination regimen with dexamethasone in a patient receiving highly emetogenic chemotherapy.
• Claims 4–6 / 13–15 / 19–21: blood levels induced by an intravenous anti‑emetic regimen; equivalency to oral 50–500 mg netupitant + 0.075–1.0 mg palonosetron HCl; and equivalency to oral 300 mg netupitant + 0.56 mg palonosetron HCl.
• Claims 7 / 16 / 22: netupitant occupies ≥70% of striatum NK1 receptors at 72 hours.
• Claims 8–11 / 17–18 / 23: complete response, no emesis, no rescue medication, prevention of nausea, and netupitant blood levels "independently effective."

Critical framing point for §102: No single reference of record discloses all three actives (netupitant + palonosetron + dexamethasone) administered to a HEC patient. The art splits into an "NK1‑antagonist + 5‑HT3 + steroid" line (aprepitant-based) and a "netupitant" line. Every challenge actually mounted (and every rejection of record) is therefore a §103 obviousness challenge, not a §102 anticipation. I flag this per reference below.

2. References on the face of / considered during prosecution of the '297 patent

2.1 Reddy — the principal prosecution reference

• Full citation: G. K. Reddy et al., "Novel Neurokinin‑1 Antagonists as Antiemetics for the Treatment of Chemotherapy‑Induced Emesis," 3 Supportive Cancer Therapy (2006).
• Date: published April 2006 (pre‑2009, so prior art under pre‑AIA §102(b)).
• Description: Review reporting that a 5‑HT3 antagonist (identified as palonosetron) plus dexamethasone was the standard of care for highly emetic chemotherapy, and that adding an NK1 antagonist (aprepitant/casopitant) enhanced CINV treatment; lists netupitant among NK1 antagonists in development for the same use.
• Status: Listed on the cover of US 10,828,297 and relied on by the Examiner during prosecution of the family (the Examiner found Reddy rendered obvious the selection of netupitant but was "not anticipatory insofar as netupitant is not a preferred species"). IPR EX1021.
• §102 / §103: §103 only. Reddy does not disclose netupitant administered with palonosetron and dexamethasone; it discloses aprepitant‑based triple therapy and separately lists netupitant. It does not anticipate claims 1–3 (or any claim) because it lacks the claimed netupitant blood‑level limitation.

2.2 Bös — the netupitant genus reference

• Full citation: M. Bös et al., U.S. Patent No. 6,297,375 (Hoffmann‑La Roche).
• Date: issued 2001 (the IPR refers to it as "a 2001 patent").
• Description: Broad genus of NK1 antagonists; expressly identifies netupitant ("formula Ib") as a highly selective NK1 antagonist; describes use for chemotherapy‑induced emesis and reports ferret studies in which pre‑exposure netupitant "completely blocked the emesis induced by the emetogens"; notes functional/terminal half‑lives of ~18–30 h. IPR EX1014.
• Status: Among the "References Considered" during prosecution of 15/923,050.
• §102 / §103: §103 only. Bös discloses netupitant as an NK1 antagonist but is silent on palonosetron, on dexamethasone, and on any fixed/dosing regimen. It cannot anticipate claims 1–23 (no palonosetron, no dexamethasone, no blood‑level limitation). It is the reference the petitioner uses to substitute netupitant for aprepitant.

2.3 Netupitant‑synthesis/prodrug patents (cited in the specification)

• Citations: U.S. Pat. Nos. 6,297,375; 6,719,996; 6,593,472 (netupitant and prodrugs) and 6,593,472; 6,747,026; 6,806,370 (prodrugs, incl. the N‑oxide of netupitant), all Hoffmann‑La Roche.
• Dates: 2001–2004.
• Description: Compound/synthesis/formulation art for netupitant and its prodrugs.
• §102 / §103: §103 background only (compound art). None discloses the claimed palonosetron + netupitant + dexamethasone method; no anticipation.

2.4 Palonosetron art (cited in the specification)

• Citations: U.S. Pat. Nos. 5,202,333 and 5,510,486 (palonosetron synthesis); PCT WO 2004/045615, WO 2004/073714, WO 2004/067005, WO 2008/049552 (Helsinn palonosetron formulations).
• Dates: 1993/1996 (US patents); 2004 and 2008 (PCT).
• Description: Palonosetron compound, synthesis and dosage forms (including the soft‑gel capsule).
• §102 / §103: §103 background only. Disclose palonosetron alone; lack netupitant and dexamethasone. No anticipation of any '297 method claim.

2.5 Clinical/regulatory literature cited in the specification

2.6 Additional references in the family's IDS (per the '297 prosecution record / PubChem "Patent Cites")

Poli‑Bigelli et al. (2003, aprepitant + standard antiemetic therapy); Hoffmann et al., Bioorg. Med. Chem. Lett. (2005, achiral NK1 antagonists); Goldhill, "Advances in drug discovery" (2006); Reddy (2006, above); Ruhlmann (2009); Grunberg (2009); Diemunsch & Grélot, "Potential of substance P antagonists as antiemetics," in Antiemetic Therapy (Karger), 2003, pp. 78‑97; Diemunsch et al., Br. J. Anaesth. 103(1):7‑13 (2009); EMEA, "Guideline on Pharmaceutical Fixed Combination Products," Dec 18, 2006; EMEND prescribing information.

§102 / §103: All are background/obviousness‑type art. None discloses the netupitant+palonosetron+dexamethasone blood‑level method; none anticipates.

3. References asserted in the instituted IPR (IPR2025‑00949) — the live prior‑art attack

The petitioner (Azurity) organizes its obviousness grounds around a primary reference (Herrstedt) + secondary reference (Bös) foundation, with tertiary references for specific dependent‑claim limitations:

Confirmed grounds (from the petition/declaration text):

• Ground 1: claims 1–5, 8–14, 17–20, 23 obvious over Herrstedt + Bös.
• Ground 2: claims 6, 15, 21 obvious over Herrstedt + Bös + ALOXI (the 300 mg netupitant / 0.56 mg palonosetron‑HCl equivalency limitation).
• Ground 3: claims 7, 16, 22 obvious over Herrstedt + Bös + Hargreaves (the ≥70% striatal NK1 occupancy at 72 h limitation).

§102 / §103 for each: None of these anticipates under §102. Even Herrstedt (the strongest) discloses aprepitant, not netupitant, and does not disclose the claimed blood‑level/occupancy parameters. Hargreaves discloses a different (imaging) context and a 75% figure, not the claimed method. ALOXI discloses palonosetron alone. Bonadeo discloses a palonosetron formulation, not the combination method.

4. Bottom line

1. No reference cited on the face of, or against, US 10,828,297 supports a §102 anticipation of any of claims 1–23. The claims require inducing therapeutically effective blood levels of palonosetron + netupitant in a combination regimen with dexamethasone in a highly emetogenic chemotherapy patient. Every reference of record either (a) supplies palonosetron alone (Aloxi, WO 2008/049552, palonosetron US patents), (b) supplies netupitant alone (Bös US 6,297,375 and the Roche netupitant/prodrug patents), or (c) supplies a triple regimen built on aprepitant, not netupitant (Reddy, Herrstedt, Grunberg, Poli‑Bigelli, EMEND label). No single reference bridges all three actives.
2. The relevant prior art for this patent is accordingly an obviousness ( §103) combination, not an anticipation set: Herrstedt (or the cumulative Reddy) + Bös, optionally + Hargreaves (claims 7/16/22), + ALOXI (claims 6/15/21), + Herrington/Bonadeo for dependent‑claim features. This is exactly the combination asserted in the instituted IPR2025‑00949 and rejected by the Office at allowance over Reddy.
3. The patentability fight turns on the "netupitant‑specific" limitations — the 300 mg/0.56 mg blood‑level equivalency (claims 6/15/21), the ≥70% striatal NK1 occupancy at 72 h (claims 7/16/22), and "independently effective" netupitant blood levels (claims 12/18/23) — because those are the elements no single reference discloses and that the petitioner must bridge with Hargreaves/ALOXI.

Caveats: (i) I could not retrieve the complete face‑of‑patent "References Cited" table because my search session terminated; the enumeration above combines the specification's own citations with the PTAB/PubChem records and may omit some U.S. patent references listed only on the cover. (ii) I did not fabricate exact issue/publication dates where a primary source was unavailable — the 2001 (Bös), 2008 (WO 2008/049552) and 2009 (Herrstedt) dates are stated as the records describe them and should be verified against the patent's cover page before filing. (iii) The §102 designations are my legal‑analysis characterization; the Office and the PTAB treated these references under §103.

I'll research the prior art cited against this patent before building the §103 analysis.

Let me pull the '297-specific petition grounds and the key prior-art references.

Let me confirm the '297-specific grounds from the institution decision.

Obviousness Analysis — US 10,828,297 B2 under 35 U.S.C. § 103

Building on the claim text, specification and prior-art annotations already supplied in the page above; claims are not re-quoted except where the limitation is the point of the analysis.

1. Legal framework and the reference date

Two threshold points matter for § 103:

1. Pre‑AIA vs. AIA. Because the application was filed after 16 March 2013 but claims priority to 2009‑11‑18, the applicable version of § 103 turns on whether the claims are actually supported by the 2009 priority disclosure. Petitioner in the pending IPR treated the challenged claims as "effectively filed November 18, 2009," explicitly stating it "challenges the claims as if they were effectively filed November 18, 2009" and defining the level of skill as of 2009 (IPR2025‑00945 record; see the Board's discussion of the '297 filing/priority). If the priority claim fails, AIA §§ 102/103 apply and the analysis below is unchanged in substance, but the qualifying-art set expands to anything publicly available before 2018‑03‑16.
2. The page's own "prior art date" (2009‑11‑18) is an assumption, as the page states. References relied on below were publicly available well before that date, so they qualify as § 102(b) art under either framing.

One inconsistency I will not silently resolve: the Unified Patents portal entry for US‑10828297‑B2 lists priority 2009‑11‑17, application date 2018‑03‑15, grant 2020‑11‑09 and expiration 2030‑12‑16, whereas the Google Patents page lists 2009‑11‑18 / 2018‑03‑16 / 2020‑11‑10 / 2030‑12‑17. I report both; I have not verified which is correct.

2. The prior-art record relied upon

From the '297 page itself (patents cited in the background, plus material incorporated by reference):

From the co-pending IPR record for the '297 patent (Azurity v. Helsinn, IPR2025‑00949, filed 1 May 2025; listed as "Pending – Instituted" on the page):

3. Mapping independent claim 1

Claim 1 recites, in substance: preventing acute and delayed nausea and vomiting in a HEC patient by inducing therapeutically effective blood levels of palonosetron and netupitant in a combination regimen with dexamethasone. Nothing in claim 1 recites a dose, a route, a schedule, or a dosing interval.

Claims 2 and 3 are the same method with a different recited result ("achieving complete response"; "preventing nausea"). Under In re Kao / Pfizer v. Apotex, reciting a new result of a known method — where the steps are unchanged — does not ordinarily confer patentability.

4. Grounds that would render the claims obvious

Ground 1 — Herrstedt + Bös: claims 1‑4, 8‑13, 17‑19, 23.
This is the core ground. Every element of claim 1 is present except the identity of the NK₁ antagonist, and Bös supplies it. This is a textbook KSR (B) rationale — substitution of one known element for another to obtain predictable results — reinforced by In re Omeprazole (substituting one known equivalent for another) and In re Mouttet / Bayer v. Watson ("just because better alternatives exist… does not mean an inferior combination is inapt").

Ground 2 — Herrstedt + Bös + ALOXI: claims 5, 6, 14, 15, 20, 21.
The dose‑equivalence/route limitations. Bös's 10–1000 mg oral range encompasses the recited "50 to 500 mg netupitant free base"; the ALOXI label supplies "0.075 to 1.0 mg palonosetron hydrochloride" and the 0.56 mg HCl (= 0.50 mg free base) capsule figure recited in claims 6/15/21, together with the "one hour prior to chemotherapy" timing. Where the claimed range overlaps a prior‑art range and the specification shows no criticality, the burden is on the patentee (In re Peterson; In re Woodruff; MPEP 2144.05).

Ground 3 — Herrstedt + Bös + Hargreaves: claims 7, 16, 22.
The "≥70 % of striatum NK₁ receptors at 72 hours" limitation. Hargreaves teaches >75 % occupancy as the therapeutically effective threshold and teaches the PET methodology and time course. Occupancy at a given time is an inherent property of the dose administered; "mere recognition of latent properties in the prior art does not render nonobvious an otherwise known invention" (In re Baxter Travenol).

Additional grounds that would independently support obviousness:

• Herrstedt + Emend label + Bös, with Herrington supplying the single‑dose/day‑one rationale (no added benefit from multi‑day NK₁ dosing; patient convenience).
• Herrstedt + Bös + Grunberg (2009), for the "single‑day three‑drug regimen" concept (Grunberg abstract: "a more convenient single‑day three‑drug antiemetic regimen").
• Hoffmann‑La Roche netupitant patents (US 6,297,375 / 6,593,472 / 6,719,996) + Helsinn palonosetron patents (US 5,202,333; WO 2004/045615; WO 2004/067005; WO 2008/049552) + Emend label + Jordan (2007) — a purely documentary combination in which the '297 page itself supplies the netupitant and palonosetron references and the dexamethasone minimum‑effective‑dose baseline.
• Herrstedt + Bös + casopitant/PONV art (Ruhlmann; Pellegatti; Diemunsch) merely confirms that NK₁ antagonists were an established, actively pursued antiemetic class by 2009.

5. Why a POSA would have been motivated to combine

1. Same mechanism, same target. Aprepitant and netupitant are both selective NK₁ (substance P) receptor antagonists. Substitution within a known class is the paradigm of predictable combination, and the class was explicitly framed as first‑generation (aprepitant) vs. second‑generation agents.
2. Herrstedt's own express invitation. Herrstedt describes the NK₁ antagonist as a class addition to the 5‑HT₃/dexamethasone backbone and names palonosetron as the preferred/improved 5‑HT₃ antagonist — i.e., the reference itself suggests the very combination claimed.
3. Bös's explicit antiemetic teaching. Bös does not merely list netupitant in a genus; it describes it as "a highly selective" NK₁ antagonist and reports that pre‑exposure "completely blocked the emesis induced by the emetogens" in ferrets — a reasonable expectation of antiemetic success in humans.
4. Dose selection was enabled, not blind. Hargreaves supplies a quantitative receptor‑occupancy target (>75 %) and the PET method to hit it; Bös supplies a proposed oral range encompassing the claimed doses. This defeats any "unpredictable dose optimization" argument.
5. Dexamethasone interaction was known. Herrstedt discloses that aprepitant roughly doubles dexamethasone AUC, providing the reason to co‑administer dexamethasone at a reduced dose — and the '297 specification's own Example 3 and FIG. 4 confirm the same effect for netupitant rather than showing something new.
6. Convenience / formulation. Richardson‑Vicks v. Upjohn (122 F.3d 1476) — a single‑unit dosage of drugs previously co‑prescribed separately is obvious as a matter of law, regardless of synergy evidence. This is directly relevant to the combined‑capsule portions of the specification.

6. The dependent‑claim layer

7. The patentee's counterarguments and how they have fared

The '297 page's entire nonobviousness story rests on the assertion that "netupitant is active against nausea," that aprepitant "show[ed] no meaningful effect against nausea," and on the ~96‑hour striatal binding claim (Summary of the Invention). The pending IPR record shows these are contested:

• Nausea vs. emesis may be a distinction without a difference in the art. The Emend label's "complete protection" endpoint incorporates no significant nausea (VAS < 25 mm) and was statistically significant; the label also reports a 66 % → 73 % improvement in no‑significant‑nausea.
• The patent's own data are marginal. In the '297 page's Table 5/6, the aprepitant regimen achieved 86.6 % CR overall vs. 89.6 % for palo + netupitant 300 mg, and nausea/significant‑nausea values are close across arms; the "Palo + Aprep 285 mg" column (N = 41) derives from Grunberg, is a non‑comparable study design, and Grunberg used a non‑standard aprepitant day‑1 dose (285 mg) and single‑day dexamethasone.
• The Rule 132 evidence that persuaded the examiner is under attack. The Director's 19 Sep 2025 decision referring the related petitions to the Board found that petitioner "persuasively argues that the data and evidence presented to the patent examiner indicates that the results may not have been unexpected," because "the overall effect for no nausea and no significant nausea for palonosetron and netupitant was nearly the same as that of palonosetron and aprepitant."
• Nexus. The commercial product (AKYNZEO®) does not include dexamethasone, while the '297 claims require a "combination regimen with dexamethasone" — a coextensiveness gap that weakens the commercial‑success argument.

8. Bottom line

On the record above, claims 1‑4, 8‑13, 17‑19 and 23 would have been prima facie obvious over Herrstedt in view of Bös; claims 5, 6, 14, 15, 20 and 21 over Herrstedt + Bös + ALOXI; and claims 7, 16 and 22 over Herrstedt + Bös + Hargreaves, with Herrington, Grunberg, the Emend label and Jordan (2007) available as secondary rationales (single‑day dosing, convenience, and a known dexamethasone‑sparing interaction). The strongest single rationale is KSR factor (B): substitution of a known, art‑recognized NK₁ antagonist for another known NK₁ antagonist in an established triple antiemetic regimen, with the class's mechanism and receptor‑occupancy/efficacy relationship supplying a reasonable expectation of success.

The nonobviousness case, if any, must come from (i) unexpected efficacy against nausea specifically, (ii) the five‑day duration from a single dose, or (iii) unexpected netupitant‑palonosetron PK interaction — each of which is presently contested on the IPR record and each of which must be shown to be commensurate with the full claim scope (claims 1‑3, for instance, recite no dose at all).

Confidence and sourcing caveats

• I have not independently reviewed the full IPR2025‑00949 petition, its exhibits (Herrstedt EX1010, Bös EX1014, Hargreaves EX1012, Herrington EX1016, ALOXI EX1015, Bonadeo EX1017), or the '949 institution decision text. The ground‑to‑claim mapping above is taken from Dr. Peroutka's declaration in the companion proceeding (which states Ground 1 = claims 1‑4, 8‑13, 17‑19, 23; Ground 2 = claims 5‑6, 14‑15, 20‑21; Ground 3 = claims 7, 16, 22) and from the Board's institution summary in IPR2025‑00945.
• The exact publication dates of Hargreaves and Herrington (and whether Grunberg falls before 18 Nov 2008 or only before 18 Nov 2009) determine whether they are § 102(b) or § 102(a) art; I did not verify those dates.
• I could not confirm whether a final written decision in IPR2025‑00949 has issued as of today; the page lists it only as "Pending – Instituted."
• Claim numbers, reference identifiers and dates are reproduced literally from the sources as retrieved; I have not corrected the 2009‑11‑17/11‑18 discrepancy noted in § 1.

Primary sources: https://patents.google.com/patent/US10828297/en · https://portal.unifiedpatents.com/[ptab](/ptab)/case/IPR2025-00949 · https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/2%3A22-cv-04635 · https://www.docketalarm.com/cases/PTAB/IPR2025-00945/AZURITY_PHARMACEUTICALS_INC/docs/05-01-2025-Petitioner/Exhibit-1009-Expert_Declaration_of_Dr_Stephen_J_Peroutka.pdf · https://pubchem.ncbi.nlm.nih.gov/patent/US10828297